Chicago—Cabozantinib offers a new treatment standard for patients with advanced renal cell carcinoma (RCC) after antiangiogenic therapy, according to final results of the Phase III METEOR trial.
The METEOR results are “clinically meaningful, especially in second-line” treatment of RCC patients, according to lead investigator Toni K. Choueiri, MD, the director of the Lank Center for Genitourinary Oncology and the Kidney Cancer Center at Dana-Farber Cancer Institute, in